Arjun Vasant Balar, Matthew D. Galsky, Arlene O. Siefker-Radtke, Scott T. Tagawa, Matthew I. Milowsky

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Urothelial cancer is a chemotherapy-sensitive pan-urothelial disease that arises from both the upper and lower urinary tract. Due to its rarity, the principles for management of upper tract urothelial cancer are derived from evidence gathered in bladder cancer trials. To date, no definitive evidence has differentiated upper tract from lower tract cancer and both are managed similarly. Epidemiologic observations, tissue-based genetic studies, and recent subset analyses from randomized trials suggest potential differences between upper tract and bladder cancers which will need to be validated in prospective trials. This chapter will review the current role for perioperative chemotherapy in high-grade upper tract urothelial cancer as well as the use of chemotherapy in advanced disease.

Original languageEnglish
Title of host publicationUpper Tract Urothelial Carcinoma
PublisherSpringer New York
Number of pages11
ISBN (Electronic)9781493915019
ISBN (Print)9781493915002
StatePublished - 1 Jan 2015


  • Muscle-invasive bladder cancer
  • Renal pelvis cancer
  • Transitional cell cancer
  • Upper tract urothelial or transitional cell cancer
  • Ureter cancer
  • Urothelial cancer


Dive into the research topics of 'Chemotherapy'. Together they form a unique fingerprint.

Cite this